Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Understanding RSV: Severe Disease and the Long Term Consequences

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03756766
Recruitment Status : Recruiting
First Posted : November 28, 2018
Last Update Posted : November 28, 2018
Sponsor:
Collaborators:
Innovative Medicines Initiative
Respiratory syncytial virus consortium in Europe
Information provided by (Responsible Party):
University of Oxford

Brief Summary:
The study design is a case-control, sample based study. 275 cases (Group 1), infants <12 months old with RSV infection and 40 controls (Group 2), otherwise healthy infants <12 months old without RSV infection will be recruited. Samples will be taken on enrolment and for infants in Group 1; repeated at 7 weeks convalescence. There will be annual follow up by questionnaire for up to 3 years and a minimum of 1 year, depending at what stage in the study the infant is enrolled (study end is December 2021).

Condition or disease Intervention/treatment
Respiratory Syncytial Virus (RSV) Diagnostic Test: RSV point of care testing

Detailed Description:

Human respiratory syncytial virus (RSV) causes severe disease in the very young, elderly and in high risk groups. Worldwide in 2005 there were an estimated 34 million cases of acute lower respiratory tract infection (ALRI), 3.4 million ALRI hospitalisations and 55,000 to 199,000 deaths associated with RSV in children <5 years old. RSV infection in childhood is associated with subsequent wheezing and asthma. These long-term sequelae pose a substantial additional burden on healthcare systems. There is a parallel need to assemble clinical resources to identify the correlates of severe RSV disease for clinical management, classification of disease severity in clinical trials and identification of biomarkers for severe disease, which are currently lacking.

Group 1: Infants under 12 months with an RSV infection will have nasopharyngeal swabs, blood, urine and stool samples taken at the onset of infection and again 6 - 8 weeks later, in convalescence. An online diary will be completed for 2 weeks during illness to record the participant and parent health. The participant and their family will be followed up annually by questionnaire, for a maximum of 3 years. When the study data are analysed, the infants will be subdivided into 4 further groups; healthy infants requiring hospitalisation, healthy infants not requiring hospitalisation, infants with co-morbidity, requiring hospitalisation and infants with a co-morbidity not requiring hospitalisation. Group 2: Well, healthy infants, under 12 months with no acute respiratory infection will have nasopharyngeal swab,blood, urine and stool samples taken on enrolment. They will receive a follow up contact 7 days after enrolment to assess if they have developed any illness. The participant and their family will be followed up annually by questionnaire, for a maximum of 3 years.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 315 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: REspiratory Syncytial Virus Consortium in EUrope (RESCEU):Presumed Risk Factors and Biomarkers for RSV-related Severe Disease and Related Sequelae
Actual Study Start Date : December 19, 2017
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
RSV positive ARTI

RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).

Group 1 participants are categorised into 4 groups as follows:

Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.

Group 1c & 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively.

Diagnostic Test: RSV point of care testing
Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
Other Names:
  • Venepuncture
  • Nasopharyngeal swabs
  • stool sample
  • Urine sample

Healthy controls

This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.

This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only.




Primary Outcome Measures :
  1. Ribonucleic acid (RNA) transcripts (Transcriptomics) that are up and down regulated in severe RSV infection [ Time Frame: 8 weeks ]
    Analysis of blood to determine cellular expression of RNA during a severe, acute RSV respiratory tract infection

  2. Cellular protein concentration changes (proteomics) in response to severe RSV infection [ Time Frame: 8 weeks ]
    Analysis of blood samples to determine how cellular protein concentrations change in response to severe RSV infection

  3. Cellular metabolite concentration changes associated with severe RSV disease [ Time Frame: 8 weeks ]
    Analysis of urine and blood to identify which metabolic pathways are up-regulated at a cellular level following severe RSV infection. This is determined by measuring metabolic by-products


Secondary Outcome Measures :
  1. Ribonucleic acid (RNA) transcripts that are up or down regulated and contribute to respiratory sequelae following RSV infection in infants [ Time Frame: 3 years ]
    Analysis of blood samples will determine changes in cellular RNA associated with RSV infection.

  2. Cellular protein concentration changes (Proteomics) affecting respiratory sequelae following RSV infection in infants [ Time Frame: 3 years ]
    Analysis of blood to determine how cellular protein production is up or down regulated in response to RSV infection to correlate with subsequent respiratory sequelae

  3. Cellular metabolite concentration changes that contribute to respiratory sequelae following RSV infection [ Time Frame: 3 years ]
    Analysis of blood and urine to determine which cellular metabolites are produced in increasing quantities during RSV infection and which are subsequently responsible for respiratory sequelae.

  4. Respiratory sequelae following RSV infection in infants [ Time Frame: 3 years ]

    Respiratory sequelae in participants will be determined by completion of a baseline questionnaire followed by an annual questionnaire for a maximum of 3 years.

    The questionnaires record patient demographics, number of siblings, family history of atopy, exposure to household smoke and pets and the ability of the child and family members to complete their usual activities


  5. Viral load associated with mild and severe RSV disease [ Time Frame: 8 weeks ]
    Nasopharyngeal swabs will be taken at baseline and at 6-8weeks to measure viral load

  6. Genetic sequence of RSV associated with mild and severe disease [ Time Frame: 8 weeks ]
    Nasopharyngeal samples will be taken at baseline and at 6-8weeks do determine the genetic sequencing of the Respiratory Syncytial Virus.

  7. Cellular immune response during RSV infection [ Time Frame: 8 weeks ]
    Whole blood will be used for flow cytometric cell phenotyping to determine which immune cells are activated in response to RSV

  8. Cytokine release associated with severe RSV disease [ Time Frame: 8 weeks ]
    Whole blood will be used to perform intracellular cytokine staining in response to RSV infection

  9. Altered gene expression associated with severe RSV disease [ Time Frame: 8 weeks ]
    Blood sampling to determine epigenetic changes associated with RSV infection

  10. RSV disease severity [ Time Frame: 8 weeks ]

    This is determined using a standardized respiratory clinical severity score (ReSVinet) which is performed at baseline.

    This score has 7 subscales;

    1. Feeding intolerance (Score 0-3)
    2. Medical intervention (score 0-3)
    3. Respiratory difficulty (score 0-3)
    4. Respiratory frequency (score 0-3)
    5. Presence of apnoea (either 0, or 3)
    6. General condition (score 0-3)
    7. fever (0-2) The total score is determined by adding each component part. The total score is from 0-20. A score of 0 reflects very mild disease whilst a score of 20 indicates severe disease

  11. Health care costs and resource use [ Time Frame: 3 years ]
    This will be determined using annual questionnaires sent to participants. The questions include: visits to healthcare providers (hospital, GP), number of admissions and duration where applicable and medication use.

  12. Interruption to normal activities associated with RSV disease [ Time Frame: 3 years ]

    Baseline parental questionnaire followed by 14 day symptom diary at onset of illness. Subsequent annual questionnaire for total of 3 years to determine subsequent disease sequelae.

    These questionnaires record symptom severity, duration of symptoms, whether the symptoms affect activities of daily living and a record of persisting symptoms. The follow up questionnaires will extract information about subsequent respiratory symptoms (cough, wheeze), whether the participant has required subsequent review by a healthcare practitioner or been admitted to hospital and during of admission. It also records the need for ongoing medications.

    The information extracted is qualitative in nature. There is no scale used for recording this information.



Biospecimen Retention:   Samples With DNA
Participants that enrol in Group 1 will have additional consent to retain specimens for the biobank.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 12 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Infants less than 12 months old who present to their GP of to hospital with RSV positive respiratory disease.
Criteria

Inclusion Criteria: All of the following must apply

  • parent/carer of the infant is willing and able to give informed consent for participation in the study
  • Male or female, less than 12 months of age at enrolment
  • Parent has a telephone

For group 1 only:

  • Hospitalised for <48 hours at enrolment or within 96 hours of onset of illness
  • Live near enough to a participating study centre for the 6-8 week home visit

Exclusion Criteria:

  • Infants who have received treatment for RSV infection (eg: ribavirin)
  • Infants who have had prior exposure to an RSV vaccine or medication
  • Infants who have received preventative therapy for RSV (eg; palivizumab)
  • Infants who have received oral steroids or montelukast within 7days of enrolment on the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03756766


Contacts
Layout table for location contacts
Contact: Andrew Pollard 01865 611400 andrew.pollard@paediatrics.ox.ac.uk

Locations
Layout table for location information
United Kingdom
Oxford University Hospitals NHS Trust Recruiting
Oxford, United Kingdom
Contact: Andrew J Pollard, PhD    01865611400    andrew.pollard@paediatrics.ox.ac.uk   
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine Recruiting
Oxford, United Kingdom
Principal Investigator: Andrew J Pollard         
Sponsors and Collaborators
University of Oxford
Innovative Medicines Initiative
Respiratory syncytial virus consortium in Europe
Investigators
Layout table for investigator information
Study Chair: Andrew Pollard Oxford Vaccine Group
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT03756766    
Other Study ID Numbers: OVG 2017/02
First Posted: November 28, 2018    Key Record Dates
Last Update Posted: November 28, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymised individual participant data sets will be shared with other researchers within the RESCEU consortium. These data sets will include information from participants baseline and annual questionnaires and results from bloods, respiratory samples, urine and stool specimens taken at onset of RSV illness and at 6-8 weeks convalescence.
Supporting Materials: Study Protocol
Time Frame: Data will be shared between researchers within the RESCEU consortium as soon as available during the study period. This is currently ongoing. Sharing of the final study information will occur 12-24 months after completion.
Access Criteria: During the study period only researchers involved within the RESCEU consortium will have access to the anonymised individual participant data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No